| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30029338 | HIV | ENSG00000026508.21 | protein_coding | CD44 | No | No | 960 | P16070 |
| TVIS30017833 | HIV | ENSG00000026508.21 | protein_coding | CD44 | No | No | 960 | P16070 |
| TVIS30017952 | HIV | ENSG00000026508.21 | protein_coding | CD44 | No | No | 960 | P16070 |
| TVIS20026789 | HPV | ENSG00000026508.21 | protein_coding | CD44 | No | No | 960 | P16070 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | CD44 |
|---|---|
| DrugBank ID | DB06550 |
| Drug Name | Bivatuzumab |
| Target ID | BE0001113 |
| UniProt ID | P16070 |
| Regulation Type | |
| PubMed IDs | 14530488 |
| Citations | Postema EJ, Borjesson PK, Buijs WC, Roos JC, Marres HA, Boerman OC, de Bree R, Lang M, Munzert G, van Dongen GA, Oyen WJ: Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer. J Nucl Med. 2003 Oct;44(10):1690-9. |
| Groups | Investigational |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | |
| PharmGKB | |
| ChEMBL |
